TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17764004

Group type: EXPERIMENTAL
Intervention: Splint therapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Self-therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study: 16898279

Group type: EXPERIMENTAL
Intervention: Medium tempo music at low and moderate exercise intensities
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fast tempo music at high exercise intensity
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Comparison of medium vs slow tempo and fast vs slow tempo music
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Linear relationship between exercise intensity and music tempo preference
Number of subjects: 29
Study: 15641498

Group type: EXPERIMENTAL
Intervention: Fuji IX
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Fuji Plus
Number of subjects: 208
Study: 10992179

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen
Number of subjects: 10

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Desogestrel
Number of subjects: 10

Group type: COMPARATOR
Intervention: Norethindrone
Number of subjects: 10
Study: 8806331

Group type: EXPERIMENTAL
Intervention: Prehospital thrombolytic therapy (recombinant tissue plasminogen activator)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Hospital thrombolytic therapy (recombinant tissue plasminogen activator)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Prehospital thrombolytic therapy
Number of subjects: 360

Group type: COMPARATOR
Intervention: Hospital thrombolytic therapy
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy within < 70 minutes from symptom onset
Number of subjects: 360

Group type: COMPARATOR
Intervention: Thrombolytic therapy after 70 minutes from symptom onset
Number of subjects: 360
Study: 1293424

Group type: EXPERIMENTAL
Intervention: Jogging 2h/week for 4 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 33
Study: 6397969

Group type: EXPERIMENTAL
Intervention: De-Nol liquid (4 X 5 ml)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin A (3 X 50,000 IU)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sucralfate (4 X 1 g)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pirenzepine (3 X 50 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 100
Study: 30955915

Group type: EXPERIMENTAL
Intervention: Tipapkinogen sovacivec (TS) vaccine
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 29486059

Group type: EXPERIMENTAL
Intervention: Metaphoric framing in high-severity condition
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Metaphoric framing in low-severity condition
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Literal framing in high-severity condition
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Literal framing in low-severity condition
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Metaphoric framing
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Literal framing
Number of subjects: 354
Study: 26254687

Group type: EXPERIMENTAL
Intervention: Project SHARE intervention (personalized patient report, educational materials on alcohol and aging, brief provider intervention, telephone health educator intervention)
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Project SHARE intervention
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 1049
Study: 25099983

Group type: EXPERIMENTAL
Intervention: Live saxophone music therapy for 30 minutes
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study: 21924651

Group type: EXPERIMENTAL
Intervention: Tulathromycin intramuscularly
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Azithromycin monotherapy orally
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Azithromycin in combination with rifampin orally
Number of subjects: 128

Group type: COMPARATOR
Intervention: Glucose orally as a placebo
Number of subjects: 128
Study: 20433566

Group type: EXPERIMENTAL
Intervention: New daytime at-home bleaching system (28% carbamide peroxide gel) with a non-custom-fit tray for 20 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional overnight at-home bleaching system (10% carbamide peroxide gel) with a custom-fit tray for 6 to 8 hours
Number of subjects: 20
Study: 18536860

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg once daily
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 16189335

Group type: EXPERIMENTAL
Intervention: 1.0 mg x kg(‐1) ketamine (Group K)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.0 mg x kg(‐1) ketamine and 0.25% bupivacaine (Group BK)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 60
Study: 12378045

Group type: EXPERIMENTAL
Intervention: 1,000 mg oral ascorbic acid (AA) preoperatively
Number of subjects: 54

Group type: COMPARATOR
Intervention: No ascorbic acid (AA) preoperatively
Number of subjects: 54
Study: 10434238

Group type: EXPERIMENTAL
Intervention: Bosentan (500 mg twice daily for 10 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (twice daily for 10 days)
Number of subjects: 12
Study: 7810935

Group type: EXPERIMENTAL
Intervention: Continuous aspiration of subglottic secretions
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 190
Study: 1971741

Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Diphenhydramine 50 mg (positive control)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (negative control)
Number of subjects: 15
Study: 423667

Group type: EXPERIMENTAL
Intervention: Dapsone (diaminodiphenylsulfone)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 64
Study: 31269044

Group type: EXPERIMENTAL
Intervention: Main perpetrator programme
Number of subjects: 228
Study: 29412076

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (BR; ∼800 mg/d)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (PLA; ∼0.5 mg/d)
Number of subjects: 52
Study: 27009147

Group type: EXPERIMENTAL
Intervention: Curved stem THA (Collum Femoris Preserving stem)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Straight stem THA (conventional uncemented straight stem)
Number of subjects: 150
Study: 24905687

Group type: EXPERIMENTAL
Intervention: Day-care management under continuous regional anaesthesia (popliteal sciatic nerve block)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Inpatient management under continuous regional anaesthesia (popliteal sciatic nerve block)
Number of subjects: 120
Study: 22918596

Group type: EXPERIMENTAL
Intervention: Levothyroxine + Selenomethionine
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Selenomethionine
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: COMPARATOR
Intervention: Healthy Control
Number of subjects: 155
Study: 20113411

Group type: EXPERIMENTAL
Intervention: NGX-4010 (capsaicin 640 microg/cm(2), 8%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control patch
Number of subjects: 0
Study: 18030234

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) monotherapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Interferon plus lamivudine combination therapy
Number of subjects: 31
Study: 12043854

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.25 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.5 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12798837

Group type: EXPERIMENTAL
Intervention: Management group (heart failure diary, education sessions)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Management group (self-weighing)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Management group (knowledge of self-management)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Management group (daily weight monitoring)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Management group (attendance at education sessions)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Management group (provision of scales)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 197
Study: 10344223

Group type: EXPERIMENTAL
Intervention: Screening protocol including PSA, DRE, and TRUS
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Screening protocol
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Predictive index model
Number of subjects: 1000
Study: 7560229

Group type: EXPERIMENTAL
Intervention: Triclosan
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline and alcohol solutions
Number of subjects: 10
Study: 2020505

Group type: EXPERIMENTAL
Intervention: Soy-based, lactose-free formula alternating with oral rehydration solution (early feeding)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oral rehydration solution alone (control group)
Number of subjects: 56
Study: 6760074

Group type: EXPERIMENTAL
Intervention: H1 antagonist (diphenhydramine 50 mg iv)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: H2 antagonist (cimetidine 300 mg iv)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31888726

Group type: EXPERIMENTAL
Intervention: Teacher Anxiety Program for Elementary Students (TAPES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard professional development seminar
Number of subjects: 0
Study: 28334365

Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib for 3 years
Number of subjects: 341

Group type: COMPARATOR
Intervention: Adjuvant imatinib for 1 year
Number of subjects: 341
Study: 26363442

Group type: EXPERIMENTAL
Intervention: Adaptic II
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clearfil Posterior (CP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Occlusin (O)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 23471307

Group type: EXPERIMENTAL
Intervention: Antibacterial prophylaxis
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Prophylactic G-CSF
Number of subjects: 897

Group type: COMPARATOR
Intervention: Mandatory hospitalization
Number of subjects: 897
Study: 21360596

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg, single oral dose)
Number of subjects: 6
Study: 19532050

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New ART agents and fixed-dose combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ART adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cART initiation
Number of subjects: 0
Study: 17601463

Group type: EXPERIMENTAL
Intervention: MRI findings in the neutral position
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MRI findings in the provocative position
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Positional change values in MRI
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Minimum costoclavicular distance
Number of subjects: 29
Study: 15122774

Group type: EXPERIMENTAL
Intervention: Synbiotic preparation (n = 20)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Fermentable fiber alone (n = 20)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 55
Study: 10791112

Group type: EXPERIMENTAL
Intervention: Infection with Chlamydia pneumoniae
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infection with Mycoplasma pneumoniae
Number of subjects: 0
Study: 9116392

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy (n = 61)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo (n = 70)
Number of subjects: 152

Group type: COMPARATOR
Intervention: PA spine BMD
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Vertebral body BMD
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Width-adjusted vertebral body BMD
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Mid-vertebral body BMD
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Width-adjusted mid-vertebral body BMD
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Femoral neck BMD
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Trochanter BMD
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Ward's triangle BMD
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Total body BMD
Number of subjects: 152
Study: 1670725

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 188

Group type: COMPARATOR
Intervention: Whole-cell vaccine
Number of subjects: 188
Study: 6365873

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (250 mg 6 hourly iv)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Cefazolin (1000 mg 6 hourly iv)
Number of subjects: 186
Study: 30877239

Group type: EXPERIMENTAL
Intervention: Low endothelial shear stress (ESS)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Low ESS
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Standalone IVUS‐VH
Number of subjects: 68
Study: 30458850

Group type: EXPERIMENTAL
Intervention: pre-CBT digital psychoeducation intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: NHS choices website for CBT
Number of subjects: 80
Study: 26454322

Group type: EXPERIMENTAL
Intervention: Intravenous haemocoagulase
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 22713145

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 20381871

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 392

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 392
Study: 18551110

Group type: EXPERIMENTAL
Intervention: Food temptation
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 97
Study: 15860476

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention consisting of six sessions and maintenance phase with one home and three brief telephone sessions
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 127

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 127
Study: 12432174

Group type: EXPERIMENTAL
Intervention: CHO/Ex (Carbohydrate during exercise)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CHO/NoEx (Carbohydrate without exercise)
Number of subjects: 13

Group type: COMPARATOR
Intervention: NoCHO/Ex (Non-caloric placebo during exercise)
Number of subjects: 13

Group type: COMPARATOR
Intervention: NoCHO/NoEx (Non-caloric placebo without exercise)
Number of subjects: 13
Study: 10597756

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4698
Study: 8558671

Group type: EXPERIMENTAL
Intervention: 5 ml. 1% lidocaine
Number of subjects: 64

Group type: COMPARATOR
Intervention: 5 ml. saline (0.9% sodium chloride)
Number of subjects: 64
Study: 1678700

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg kg‐1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg kg‐1)
Number of subjects: 50
Study: 6389815

Group type: EXPERIMENTAL
Intervention: Soluble aspirin given by mouth in divided dosage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 31617926

Group type: EXPERIMENTAL
Intervention: Active interventions (physical exercise, nutritional enhancement, cognitive training, combined treatment)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Active interventions
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 92
Study: 29162334

Group type: EXPERIMENTAL
Intervention: IR‐Tac
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LCPT
Number of subjects: 50
Study: 26654880

Group type: EXPERIMENTAL
Intervention: dALAN exposure (5 lux)
Number of subjects: 23
Study: 24354913

Group type: EXPERIMENTAL
Intervention: Linguistic agency assigned to HPV (e.g., 'HPV preys on millions of people')
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Linguistic agency assigned to vaccination (e.g., 'Vaccination guards people')
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Linguistic agency assigned to HPV and vaccination
Number of subjects: 361
Study: 22405597

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/day) for 2 years
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Males with Kallmann syndrome
Number of subjects: 28
Study: 20670438

Group type: EXPERIMENTAL
Intervention: Intracarpal injections of 1 ml triamcinolonacetonide 10 mg/ml (TCA)
Number of subjects: 69

Group type: COMPARATOR
Intervention: 1 ml NaCl (placebo)
Number of subjects: 69
Study: 17379125

Group type: COMPARATOR
Intervention: Traditional tidal volume ventilation (V(T), 10 mL/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (V(T), 6 mL/kg)
Number of subjects: 16
Study: 17378787

Group type: EXPERIMENTAL
Intervention: TCI-propofol and intravenously administered ketamine (n=9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: TCI-propofol alone (n=8)
Number of subjects: 17
Study: 15077028

Group type: EXPERIMENTAL
Intervention: Reconstruction of tributaries from segment 5 or 8 (n=11)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reconstruction of the middle hepatic vein (MHV) (n=9)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard grafts with only right-sided hepatic vein(s) (n=45)
Number of subjects: 20
Study: 10861141

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 60

Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 60
Study: 9116609

Group type: EXPERIMENTAL
Intervention: i.v. acyclovir 500 mg/m2 three times a day from 5 days before transplant to 30 days after transplant followed by oral acyclovir 800 mg four times a day for a further 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: i.v. acyclovir followed by placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: 400 mg oral acyclovir four times a day followed by placebo (control)
Number of subjects: 0
Study: 8237870

Group type: EXPERIMENTAL
Intervention: Selenomethionine (2.7 mumol Se)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (2.9 mumol Se)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsupplemented women
Number of subjects: 0
Study: 3921097

Group type: EXPERIMENTAL
Intervention: Myringotomy alone
Number of subjects: 4860

Group type: EXPERIMENTAL
Intervention: Antibiotics alone
Number of subjects: 4860

Group type: EXPERIMENTAL
Intervention: Myringotomy and antibiotics combined
Number of subjects: 4860

Group type: COMPARATOR
Intervention: Nose drops and analgesics
Number of subjects: 4860
Study: 1097603

Group type: EXPERIMENTAL
Intervention: Phenothiazine (+/‐)‐10‐3‐dimethylamino‐2‐methylpropyl)‐2‐valeroylphenothiazine, 40 mg daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 9
Study: 31232274

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of nifedipine GITS 60 mg and candesartan 32 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Loose combination of nifedipine and candesartan
Number of subjects: 48
Study: 30279197

Group type: EXPERIMENTAL
Intervention: Single antiplatelet therapy (SAPT) - aspirin only
Number of subjects: 870

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) for an additional six months
Number of subjects: 870
Study: 27039300

Group type: EXPERIMENTAL
Intervention: SMS4BG (text message-based diabetes self-management support) in addition to usual care
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 1000
Study: 24356620

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) 500 µg q3w
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Control (no darbepoetin alfa)
Number of subjects: 1234
Study: 22537073

Group type: EXPERIMENTAL
Intervention: Eye movement desensitisation and reprocessing (EMDR) - eye movements (EM)
Number of subjects: 0
Study: 19942640

Group type: EXPERIMENTAL
Intervention: 520 mg cocoa flavanols (CF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 994 mg cocoa flavanols (CF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matched control
Number of subjects: 30
Study: 17367490

Group type: EXPERIMENTAL
Intervention: Local ISI calibration
Number of subjects: 27

Group type: COMPARATOR
Intervention: Direct INR
Number of subjects: 27
Study: 16135584

Group type: EXPERIMENTAL
Intervention: 600 mug misoprostol orally
Number of subjects: 317

Group type: COMPARATOR
Intervention: Manual vacuum aspiration
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 317
Study: 12045677

Group type: EXPERIMENTAL
Intervention: Chronic suppressive fluconazole therapy
Number of subjects: 518

Group type: COMPARATOR
Intervention: Episodic fluconazole therapy
Number of subjects: 518
Study: 10463841

Group type: EXPERIMENTAL
Intervention: SLE patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SLE patients with severe disease
Number of subjects: 0
Study: 8545290

Group type: EXPERIMENTAL
Intervention: Nilvadipine (4 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2483786

Group type: EXPERIMENTAL
Intervention: Crilanomer
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Dextranomer
Number of subjects: 95
Study: 875139

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 31230938

Group type: EXPERIMENTAL
Intervention: CCTA + CTP strategy (Group A)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Usual care (Group B)
Number of subjects: 2000